AR121675A1 - 3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52 - Google Patents
3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52Info
- Publication number
- AR121675A1 AR121675A1 ARP210100766A ARP210100766A AR121675A1 AR 121675 A1 AR121675 A1 AR 121675A1 AR P210100766 A ARP210100766 A AR P210100766A AR P210100766 A ARP210100766 A AR P210100766A AR 121675 A1 AR121675 A1 AR 121675A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- following
- phenoxiazethidin
- pyrazines
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos derivados de 3-fenoxiazetidin-1-il-pirazina con actividad agonista de GPR52, una composición farmacéutica que contiene al menos uno de éstos compuestos y el empleo de los mismos para el tratamiento de trastornos del SNC tales como esquizofrenia, enfermedad de Parkinson y enfermedad de Alzheimer. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque A se selecciona del grupo Aᵃ que consiste en lo siguiente: un resto de fórmula (2) y (3); R¹ se selecciona del grupo R¹ᵃ que consiste en lo siguiente H- y F-; R² se selecciona del grupo R²ᵃ que consiste en lo siguiente H- y F-; R³ se selecciona del grupo R³ᵃ que consiste en lo siguiente halógeno, F₂HCO-, F₃CO-, F₂HC- y F₃C-; R⁴ se selecciona del grupo R⁴ᵃ que consiste en lo siguiente H- y alquilo C₁₋₃, donde el grupo alquilo C₁₋₃ mencionado anteriormente puede estar opcionalmente sustituido con 1 a 5 sustituyentes seleccionados independientemente del grupo que consiste en flúor; o una sal de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001640P | 2020-03-30 | 2020-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121675A1 true AR121675A1 (es) | 2022-06-29 |
Family
ID=75362607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100766A AR121675A1 (es) | 2020-03-30 | 2021-03-29 | 3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11780827B2 (es) |
| EP (1) | EP4126850B1 (es) |
| JP (1) | JP7617134B2 (es) |
| KR (1) | KR20220161454A (es) |
| CN (1) | CN115697997B (es) |
| AR (1) | AR121675A1 (es) |
| AU (1) | AU2021250303A1 (es) |
| BR (1) | BR112022018996A2 (es) |
| CA (1) | CA3176265A1 (es) |
| CO (1) | CO2022014886A2 (es) |
| CR (1) | CR20220554A (es) |
| DO (1) | DOP2022000203A (es) |
| EC (1) | ECSP22080683A (es) |
| IL (1) | IL296823A (es) |
| MX (1) | MX2022012067A (es) |
| PE (1) | PE20221918A1 (es) |
| PH (1) | PH12022552553A1 (es) |
| TW (1) | TW202204343A (es) |
| WO (1) | WO2021198149A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121901A1 (es) | 2020-04-22 | 2022-07-20 | Neurocrine Biosciences Inc | Moduladores gpr52 y métodos de uso |
| CN117940420A (zh) | 2021-09-14 | 2024-04-26 | 勃林格殷格翰国际有限公司 | 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途 |
| CN119143731B (zh) * | 2024-09-13 | 2025-08-26 | 中国海洋大学 | 一种吡嗪酰胺类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002533454A (ja) | 1998-12-23 | 2002-10-08 | イーライ・リリー・アンド・カンパニー | 芳香族アミド類 |
| EP2253618A1 (en) * | 2008-02-27 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Compound having 6-membered aromatic ring |
| GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
| EP2298731A4 (en) | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| JPWO2011078360A1 (ja) | 2009-12-24 | 2013-05-09 | 武田薬品工業株式会社 | アミド化合物 |
| EP2530078A1 (en) | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| WO2011145735A1 (ja) | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2012020738A1 (ja) | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| JP6673939B2 (ja) | 2015-04-29 | 2020-04-01 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ５２に関連する障害の治療または予防に有用なｇｐｒ５２のモジュレーターとしての１−ヘテロアリール−インドリン−４−カルボキサミド |
| JP2018531926A (ja) * | 2015-09-17 | 2018-11-01 | コーダ バイオセラピューティクス， インコーポレイテッド | 神経学的障害を処置するための組成物および方法 |
-
2021
- 2021-03-29 US US17/215,759 patent/US11780827B2/en active Active
- 2021-03-29 BR BR112022018996A patent/BR112022018996A2/pt not_active Application Discontinuation
- 2021-03-29 TW TW110111402A patent/TW202204343A/zh unknown
- 2021-03-29 CA CA3176265A patent/CA3176265A1/en active Pending
- 2021-03-29 CN CN202180025462.7A patent/CN115697997B/zh active Active
- 2021-03-29 AU AU2021250303A patent/AU2021250303A1/en not_active Abandoned
- 2021-03-29 WO PCT/EP2021/058099 patent/WO2021198149A1/en not_active Ceased
- 2021-03-29 PE PE2022002146A patent/PE20221918A1/es unknown
- 2021-03-29 AR ARP210100766A patent/AR121675A1/es not_active Application Discontinuation
- 2021-03-29 KR KR1020227038002A patent/KR20220161454A/ko not_active Withdrawn
- 2021-03-29 JP JP2022559709A patent/JP7617134B2/ja active Active
- 2021-03-29 IL IL296823A patent/IL296823A/en unknown
- 2021-03-29 MX MX2022012067A patent/MX2022012067A/es unknown
- 2021-03-29 EP EP21716133.0A patent/EP4126850B1/en active Active
- 2021-03-29 PH PH1/2022/552553A patent/PH12022552553A1/en unknown
- 2021-03-29 CR CR20220554A patent/CR20220554A/es unknown
-
2022
- 2022-09-23 DO DO2022000203A patent/DOP2022000203A/es unknown
- 2022-10-18 EC ECSENADI202280683A patent/ECSP22080683A/es unknown
- 2022-10-19 CO CONC2022/0014886A patent/CO2022014886A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021250303A1 (en) | 2022-09-22 |
| CR20220554A (es) | 2023-01-09 |
| US11780827B2 (en) | 2023-10-10 |
| EP4126850B1 (en) | 2024-04-17 |
| BR112022018996A2 (pt) | 2022-11-01 |
| MX2022012067A (es) | 2022-10-13 |
| WO2021198149A1 (en) | 2021-10-07 |
| ECSP22080683A (es) | 2022-11-30 |
| CA3176265A1 (en) | 2021-10-07 |
| KR20220161454A (ko) | 2022-12-06 |
| PE20221918A1 (es) | 2022-12-29 |
| JP7617134B2 (ja) | 2025-01-17 |
| TW202204343A (zh) | 2022-02-01 |
| IL296823A (en) | 2022-11-01 |
| CO2022014886A2 (es) | 2022-10-31 |
| CN115697997A (zh) | 2023-02-03 |
| CN115697997B (zh) | 2024-07-30 |
| JP2023522307A (ja) | 2023-05-30 |
| EP4126850A1 (en) | 2023-02-08 |
| DOP2022000203A (es) | 2022-11-30 |
| PH12022552553A1 (en) | 2024-01-03 |
| US20220356172A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121675A1 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas como agonistas de gpr52 | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR090867A1 (es) | Compuestos y composiciones plaguicidas y procesos relacionados | |
| AR109349A1 (es) | Compuestos y usos | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR108011A1 (es) | Moduladores receptores de estrógenos | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| EA200400387A1 (ru) | Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний | |
| BR112014025564A2 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR090474A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
| AR101696A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| AR117006A1 (es) | Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
| AR061433A1 (es) | Compuestos de amida del acido 3-amino-tieno (2,3,b) piridina -2-carboxilico sustituido, procesos para su preparacion y usos de los mismos | |
| AR116626A1 (es) | Inhibidores de la ácido graso sintasa (fasn) | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| AR081034A1 (es) | Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central | |
| PE20201148A1 (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |